Opinion|Videos|March 25, 2024
Practical Considerations in MRD Testing in CRC
Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
The CDH17-targeting antibody-drug conjugate received the designation for previously treated advanced unresectable or metastatic colorectal cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
Dr Lee on the Optimal Duration of Adjuvant Osimertinib in EGFR+ NSCLC
5